Kura Oncology Reports Q2 2026 Earnings with Strong Revenue Growth
Kura Oncology (NASDAQ: KURA) reported financial results for the second quarter of 2026, highlighting a significant increase in net product revenue to $9.1 million—a 57% rise from the first quarter. The company also noted strong growth in new patient starts and total prescriptions, with increases of 35% and 59%, respectively. Kura maintained its collaboration revenue guidance for 2026 at between $45 million to $55 million while maintaining projections for future years. Additionally, the firm expects a substantial payment from Kyowa Kirin totaling up to $180 million to support further development of ziftomenib through pivotal trials. Despite these gains, Kura reported a net loss of $68.3 million in Q2 2026 compared to $66.1 million the previous year. The company is also advancing its precision oncology platform with promising clinical data across various cancer treatments.
Tickers: $KURA
Topics: aml_treatment biotech ziftomenib_program